



Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



Ref.:ISLL:CH:2020:

Date: 15th June, 2020

The President,
Corporate Relationship Department,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

The Vice President,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No.C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

Sub: Press Release.

Dear Sir,

Pursuant to regulation 30 of the Listing Obligations and Disclosure Requirements, 2015, please find enclosed a Press Release for dissemination to the Stakeholders of the Company.

This is for your information please.

Thanking you,

For IND-SWIFT LABORATORIES LTD.

PARDEEP VERMA
AVP-CORPORATE AFFAIRS &
COMPANY SECRETARY



Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



PRESS RELEASE

IND-SWIFT LABS TO LAUNCH GENERIC FEXOFENADINE IN THE US MARKET TIED UP WITH REPUTED GENERIC PLAYER IN USA

Ind-Swift Laboratories limited is all set to commercially launch its key API - Fexofenadine, an Anti-Histamine Drug used for the treatment of seasonal allergic rhinitis and Urticaria in US market.

The Company has tied up with a reputed generic player in USA, which had filed the ANDA using the Ind-Swift Laboratories Limited DMF. The Company has received the commercial orders and the supplies are beginning from the current quarter.

USA is a significant market for this product. Over 14% of the total turnover of the Company is contributed by the US market. The Company supplies 7-8 products commercially to the US market. The Company has been successfully inspected by the USFDA in March 2020 for the sixth time since its inception, without any 483 observations. The Company has also received EIR.

Padup Singh
Ind-Swift Laboratories Ltd.
CHANDIGARH